BHRC BLOG
BPC-157 Oral vs. Injected — What the Evidence Actually Supports
BPC-157 · Oral vs. Injected, Reviewed
Over 80% of the published research comes from one laboratory. Fewer than 30 humans have taken it. And oral absorption has never been measured in any species.
1. What BPC-157 is, and the provenance problem
BPC-157 is a synthetic pentadecapeptide — fifteen amino acids — described as a partial sequence of “Body Protection Compound,” a substance isolated from human gastric juice. It was first described in 1993. The preclinical literature reports angiogenesis and tissue repair via VEGFR2 and nitric oxide signalling through the Akt–eNOS axis, plus ERK1/2 signalling and anti-inflammatory effects.
Now the part that reframes all of it. A 2026 peer-reviewed review in Pharmaceutics quantifies the provenance of that literature: more than 80% of the published work originates from a single research group at the University of Zagreb. The review notes the absence of “independent replication across geographically and institutionally diverse laboratories” and describes this as a significant limitation by contemporary standards. The first genuinely independent pharmacokinetic dataset did not appear until 2022.
2. Is there any human trial? Be precise
“None” is slightly too strong. The accurate answer is that there is no adequately powered, controlled, published human efficacy trial for any indication — and here is what does exist:
The intravenous safety study deserves naming for what it is: two people, receiving 10 mg on day one and 20 mg on day two, with no changes in cardiac, liver, kidney, thyroid or glucose biomarkers and no side effects reported. Two people, over three days, establishes nothing about safety. It is cited constantly as if it did.
3. Oral versus injected — the strongest “no data” flag in peptides
Oral BPC-157 is the most commonly sold form and the one with the least support, so it gets the bluntest treatment here.
What is claimed: that BPC-157 is stable in human gastric juice — a finding from the Zagreb group, repeated across their reviews — and is therefore orally active.
What the pharmacokinetic record actually contains: the best and only independent PK study, published in Frontiers in Pharmacology in 2022, tested intravenous and intramuscular routes only. It did not evaluate oral bioavailability at all. What it did find:
The 2026 Pharmaceutics review states the gap explicitly: BPC-157’s human pharmacokinetic profile “remains critically undercharacterized,” and oral bioavailability in any species, under standardised fasting or fed conditions, is entirely absent from the literature.
4. Where it stands with the FDA, in 2026
The FDA’s own briefing document from July 2026 is the most authoritative statement available, and it is worth reporting in substance:
- Characterization: not well-characterized, with inconsistent naming conventions violating standard nomenclature and missing data on impurities, aggregates, microbial quality and particle size.
- Immunogenicity: as a fifteen-amino-acid peptide given parenterally or nasally, it “may pose significant risk for immunogenicity,” potentially amplified by aggregation and peptide-related impurities.
- Human safety: “There is insufficient clinical safety information to characterize the safety profile of BPC-157.”
- Nonclinical signals: repeat-dose animal studies showed altered clotting properties and liver-related changes. This directly contradicts the “zero side effects” marketing.
- Effectiveness: insufficient — and notably, no studies used the proposed oral, subcutaneous, nasal or transdermal routes.
One more practical constraint: pharmaceutical-grade active ingredient suitable for compounding does not yet exist at commercial scale for most of these peptides. Even a favourable FDA decision would not immediately produce a compliant supply.
5. Anti-doping status
BPC-157 is explicitly named on the WADA Prohibited List under S0 — Non-Approved Substances, added effective 1 January 2022, prohibited at all times, non-Specified. S0 covers any pharmacological substance with no current approval by any governmental regulatory health authority for human therapeutic use.
No Therapeutic Use Exemption is available, because a TUE requires an approved therapeutic use, which BPC-157 does not have. Sanctions have been imposed. TB-500 is separately banned under S2.3. If you are tested in any capacity — professional, collegiate, masters competition — this is disqualifying and there is no route around it.
6. What we tell patients who ask
People ask about this constantly, usually because of a tendon or a joint that is not healing. Here is the whole conversation:
- It is not an approved drug and it is not lawfully compoundable today. The April 2026 Category 2 removal was a paperwork consequence of withdrawn nominations. The July 2026 advisory vote is a recommendation the FDA has not acted on.
- The evidence is animal, and unusually concentrated. Over 80% from one laboratory, without independent replication.
- Oral product claims are not supported by pharmacokinetic data in any species.
- “Natural” and “no side effects” are not established. The FDA’s own review flags immunogenicity risk plus clotting and liver signals in repeat-dose animal work.
- Product identity is unverifiable from grey-market sources, which are not made under manufacturing standards and are not tested for impurities, aggregates or endotoxin.
- For a tendon or joint that is not healing, there are things with real controlled evidence. Progressive loading and eccentric rehabilitation, physical therapy, activity modification. And if you want an in-clinic option, joint injections and PRP have their own honest evidence — which we have also written about without inflating.
The peer-reviewed review that assessed it most carefully calls BPC-157 “investigational.” That is the right word, and it is the word we use.
1860 S Sepulveda Blvd, Los Angeles, CA 90025
(310) 861-3748 · Monday–Friday 9:00 AM – 6:00 PM, Saturday 9:00 AM – 4:00 PM
Treatment by the BHRC clinical team
4.8 stars across 287 verified reviews
Provider-led protocols, joint injections and PRP are offered here.
Consultations are free and carry no obligation.
Questions we get asked
Is oral BPC-157 absorbed?
There is no published evidence, in humans or any species, that it is absorbed intact into systemic circulation at meaningful concentrations. The best independent pharmacokinetic study tested only IV and intramuscular routes. Oral bioavailability data is entirely absent from the literature.
Is BPC-157 legal now that it was removed from Category 2?
No. Removal from Category 2 does not make a substance eligible for compounding under section 503A — the FDA has said so directly. BPC-157 has no USP monograph, is not a component of an approved drug, and is not on the 503A bulks list, so it satisfies none of the three statutory routes.
Didn’t an FDA panel just approve it?
An advisory committee voted 8–6 with one abstention to recommend it for the bulks list, tied specifically to an ulcerative colitis indication — and over the FDA’s own reviewers’ recommendation against. Advisory votes are non-binding. The FDA has taken no final action and rulemaking would be required.
Has anyone been harmed by it?
The published human exposure is fewer than 30 people, so the honest answer is that nobody knows. Absence of reported adverse events in 30 people is not evidence of safety. The FDA’s review flags immunogenicity risk and notes altered clotting and liver changes in repeat-dose animal studies.
Will it show up on a drug test?
Yes. BPC-157 is explicitly named under WADA S0, prohibited at all times, non-Specified, since January 2022. No Therapeutic Use Exemption is available because a TUE requires an approved therapeutic use.
What should I do for a tendon that won’t heal?
See someone who will image it and give you a diagnosis. Progressive loading and eccentric rehab have controlled evidence; so does appropriate activity modification. In-clinic options like PRP have their own qualified evidence — we have written about that honestly too. Start with the diagnosis.
Keep reading
- BPC-157 oral — the BHRC page
- The Glow protocol — GHK-Cu, BPC-157 and TB-500 reviewed
- The 2026 FDA peptide reclassification, explained
- TB-500 at BHRC
- Provider-led peptide and hormone protocols
- Joint injections — the evidence-based options
- PRP and PRF — honest evidence by indication
Book at any of our six locations
References
- U.S. Food and Drug Administration — Pharmacy Compounding Advisory Committee briefing document — BPC-157 (free base) and BPC-157 acetate, July 2026. fda.gov
- Pharmaceutics (2026) — BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges, formulation strategies and translational development barriers. 2026;18(5):625. mdpi.com
- Li X, et al. — Pharmacokinetics, distribution, metabolism and excretion of body-protective compound 157 in rats and dogs. Frontiers in Pharmacology 2022;13:1026182. frontiersin.org
- McGuire FP, Martinez R, Lenz A, et al. — Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med 2025. doi.org
- Lee E, Burgess K — Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med 2025;31(5):20–24 — n=2. pubmed.ncbi.nlm.nih.gov
- U.S. Food and Drug Administration — Certain bulk drug substances for use in compounding that may present significant safety risks — Category 2 and the withdrawn-nomination table. fda.gov
- U.S. Food and Drug Administration — July 23–24, 2026 meeting of the Pharmacy Compounding Advisory Committee — agenda and materials. fda.gov
- U.S. Anti-Doping Agency — Athlete advisory — explanation of key changes on the 2022 WADA Prohibited List, adding BPC-157 under S0. usada.org
- Cornell Legal Information Institute — 21 CFR § 216.23 — the 503A bulks list. law.cornell.edu
Beverly Hills Rejuvenation Center. This content is for general education and does not create a physician-patient relationship or constitute medical advice. BPC-157 is not an FDA-approved drug, does not appear on either FDA compounding bulks list, and is prohibited at all times under WADA S0. This article is an evidence review and does not describe or recommend a protocol. Candidacy, dosing, results and pricing vary by person and are confirmed at a free consultation. Reviewed by the BHRC clinical team.
